476 filings
Page 5 of 24
8-K
lnk4k
11 Feb 21
Results of Operations and Financial Condition
1:30pm
8-K
k3xada
25 Jan 21
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
8:11am
8-K
vddg846l
8 Dec 20
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
4:35pm
8-K
fq90aopl50pmfa
13 Nov 20
Other Events
8:18am
8-K
xzyf7t83lpm3p
5 Nov 20
Albireo Reports Q3 2020 Financial Results and Provides Business Update
7:40am
8-K
tp7llajtnonfnr25z9m
15 Oct 20
Departure of Directors or Certain Officers
4:33pm
8-K
8l0ltc2
10 Sep 20
Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
4:25pm
424B5
smcd4g
10 Sep 20
Prospectus supplement for primary offering
4:22pm
8-K
ohy196zo
9 Sep 20
Termination of a Material Definitive Agreement
4:22pm
8-K
agm kwq708u
8 Sep 20
Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock
4:57pm
424B5
27p4xf2wdrbzfz3mll
8 Sep 20
Prospectus supplement for primary offering
4:35pm
8-K
158bzxg3ybj
8 Sep 20
Other Events
6:40am
EFFECT
t33t fnjs
19 Aug 20
Notice of effectiveness
12:15am
8-K
roek9ah 266r
18 Aug 20
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
4:56pm
CORRESP
txaxnrh47ui
14 Aug 20
Correspondence with SEC
12:00am
UPLOAD
cy2uw031
13 Aug 20
Letter from SEC
12:00am
8-K
kquua 37i769rkjz
6 Aug 20
Albireo Reports Q2 2020 Financial Results and Provides Business Update
7:39am